Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,214
archived clinical trials in
Women's Studies

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
McCann MD Research, Inc.
mi
from
Torrance, CA
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
McCann MD Research, Inc.
mi
from
Torrance, CA
Click here to add this to my saved trials
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Women's Medical Research Group, LLC
mi
from
Clearwater, FL
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Women's Medical Research Group, LLC
mi
from
Clearwater, FL
Click here to add this to my saved trials
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
KO Clinical Research, LLC
mi
from
Fort Lauderdale, FL
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
KO Clinical Research, LLC
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Community Medical Research
mi
from
Miami Beach, FL
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Community Medical Research
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Miami Clinical Research
mi
from
Miami, FL
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Miami Clinical Research
mi
from
Miami, FL
Click here to add this to my saved trials
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Community Medical Research
mi
from
North Miami, FL
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Community Medical Research
mi
from
North Miami, FL
Click here to add this to my saved trials
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
MedPharmics, LLC.
mi
from
Metairie, LA
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
MedPharmics, LLC.
mi
from
Metairie, LA
Click here to add this to my saved trials
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Saginaw Valley Medical Research Group, LLC
mi
from
Saginaw, MI
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Saginaw Valley Medical Research Group, LLC
mi
from
Saginaw, MI
Click here to add this to my saved trials
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Drexel University College of Medicine
mi
from
Philadelphia, PA
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Drexel University College of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Magnolia OB/GYN Research Center
mi
from
Myrtle Beach, SC
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Magnolia OB/GYN Research Center
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Discovery Clinical Trials- HCWC, LLC
mi
from
Dallas, TX
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Discovery Clinical Trials- HCWC, LLC
mi
from
Dallas, TX
Click here to add this to my saved trials
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer
Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Comparison of Human Embryo Development Using Sequential and Single Media With Time-lapse Imaging
Comparison of Human Embryonic Development Using Sequential and Single Media in IVF Monitored by Time-lapse Imaging.
Status: Enrolling
Updated:  12/31/1969
Pacific Fertility Center
mi
from
San Francisco, CA
Comparison of Human Embryo Development Using Sequential and Single Media With Time-lapse Imaging
Comparison of Human Embryonic Development Using Sequential and Single Media in IVF Monitored by Time-lapse Imaging.
Status: Enrolling
Updated: 12/31/1969
Pacific Fertility Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Comparison of Human Embryo Development Using Sequential and Single Media With Time-lapse Imaging
Comparison of Human Embryonic Development Using Sequential and Single Media in IVF Monitored by Time-lapse Imaging.
Status: Enrolling
Updated:  12/31/1969
Frisco IVF
mi
from
Frisco, TX
Comparison of Human Embryo Development Using Sequential and Single Media With Time-lapse Imaging
Comparison of Human Embryonic Development Using Sequential and Single Media in IVF Monitored by Time-lapse Imaging.
Status: Enrolling
Updated: 12/31/1969
Frisco IVF
mi
from
Frisco, TX
Click here to add this to my saved trials
Comparison of Human Embryo Development Using Sequential and Single Media With Time-lapse Imaging
Comparison of Human Embryonic Development Using Sequential and Single Media in IVF Monitored by Time-lapse Imaging.
Status: Enrolling
Updated:  12/31/1969
Fertilitetscentrum
mi
from
Goteburg,
Comparison of Human Embryo Development Using Sequential and Single Media With Time-lapse Imaging
Comparison of Human Embryonic Development Using Sequential and Single Media in IVF Monitored by Time-lapse Imaging.
Status: Enrolling
Updated: 12/31/1969
Fertilitetscentrum
mi
from
Goteburg,
Click here to add this to my saved trials
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Albany, NY
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Harrisburg, PA
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Harrisburg, PA
Click here to add this to my saved trials
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated:  12/31/1969
UCLA Clinical AIDS Research and Education (CARE) Center
mi
from
Los Angeles, CA
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated: 12/31/1969
UCLA Clinical AIDS Research and Education (CARE) Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated:  12/31/1969
Ucsf Ancre
mi
from
San Francisco, CA
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated: 12/31/1969
Ucsf Ancre
mi
from
San Francisco, CA
Click here to add this to my saved trials
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated:  12/31/1969
John H Stroger Hospital of Cook County
mi
from
Chicago, IL
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated: 12/31/1969
John H Stroger Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated:  12/31/1969
Boston University Cancer Research Center
mi
from
Boston, MA
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated: 12/31/1969
Boston University Cancer Research Center
mi
from
Boston, MA
Click here to add this to my saved trials
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated:  12/31/1969
Laser Surgery Care Center
mi
from
New York, NY
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated: 12/31/1969
Laser Surgery Care Center
mi
from
New York, NY
Click here to add this to my saved trials
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh School of Medicine
mi
from
Pittsburgh, PA
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh School of Medicine
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated:  12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated: 12/31/1969
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated:  12/31/1969
University of Puerto Rico Comprehensive Cancer Center
mi
from
San Juan,
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated: 12/31/1969
University of Puerto Rico Comprehensive Cancer Center
mi
from
San Juan,
Click here to add this to my saved trials
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated:  12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV
Screening HIV-Infected Women for Anal Cancer Precursors
Status: Enrolling
Updated: 12/31/1969
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Altus Research
mi
from
Lake Worth, FL
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Altus Research
mi
from
Lake Worth, FL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Healthcare Clinical Data, Inc.
mi
from
North Miami, FL
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Healthcare Clinical Data, Inc.
mi
from
North Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
SUNY Downstate Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Lyndhurst Clinical Research
mi
from
Raleigh, NC
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Lyndhurst Clinical Research
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Drexel Vaginitis Center
mi
from
Philadelphia, PA
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Drexel Vaginitis Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Brownstone Clinical Trials
mi
from
Irving, TX
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Brownstone Clinical Trials
mi
from
Irving, TX
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Harborview ID Research Clinic
mi
from
Seattle, WA
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Harborview ID Research Clinic
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated:  12/31/1969
Lyndhurst Clinical Research
mi
from
Winston-Salem, NC
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis
Status: Enrolling
Updated: 12/31/1969
Lyndhurst Clinical Research
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
Wayne State University
mi
from
Detroit, MI
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospital
mi
from
Kansas City, MO
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
University of New Mexico
mi
from
Albuquerque, NM
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
University of Rochester
mi
from
Rochester, NY
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials